NCT02787226View on ClinicalTrials.gov

Liposomal Bupivacaine Infiltration vs Continuous Perineural Ropivacaine Infusion for Post-operative Pain After Total Shoulder Arthroplasty

PHASE4TerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

April 28, 2017

Study Completion Date

May 31, 2017

Conditions
Postoperative PainShoulder Arthritis
Interventions
DRUG

Liposomal Bupivacaine Infiltration

Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.

DRUG

Continuous Perineural Ropivicaine Infusion

Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.

Trial Locations (1)

21207

University of Maryland Rehabilitation and Orthopaedic Institute, Baltimore

Sponsors
All Listed Sponsors
collaborator

Pacira Pharmaceuticals, Inc

INDUSTRY

lead

Eric Shepard

OTHER

NCT02787226 - Liposomal Bupivacaine Infiltration vs Continuous Perineural Ropivacaine Infusion for Post-operative Pain After Total Shoulder Arthroplasty | Biotech Hunter | Biotech Hunter